Cost-effectiveness of universal childhood hepatitis A vaccination in Chile (Q56995266)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

title

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

13 January 2020

main subject

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Bruce L. Innis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

Oscar Arteaga

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

M Teresa Valenzuela

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

R Jake Jacobs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Allen S Meyerhoff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

language of work or name

English

0 references

publication date

12 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

4110-4119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization

13 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

The cost of hepatitis A infections in American adolescents and adults in 1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Type A viral hepatitis. New developments in an old disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Infectious hepatitis: detection of virus during the incubation period and in clinically inapparent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Transmission of hepatitis A through household contact.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Community wide outbreak of hepatitis A linked to children in day care centres and with increased transmission in young adult men in Florida 1988-9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Risk of exposure to hepatitis A virus among day-care workers in Israel: implications for preventive measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Hepatitis A transmitted by food

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Inactivation of hepatitis A virus in heat-treated mussels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Protection against hepatitis A by an inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Hepatitis A booster vaccination: is there a need?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Control of hepatitis A through routine vaccination of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Effectiveness of a mass hepatitis A vaccination program in preadolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Regional variation in the cost effectiveness of childhood hepatitis A immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Age-specific prevalence of antibodies to hepatitis A in Santiago, Chile: risk factors and shift in age of infection among children and young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Epidemiology and results of liver transplantation for acute liver failure in Chile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Hepatitis A shifting epidemiology in Latin America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

Cost-utility analysis of hepatitis A prevention among health-care workers in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.021

10.1016/J.VACCINE.2005.03.021

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15964479%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference